Finance

Beta
Lists
CLYM:NASDAQ
Climb Bio Inc
$13.08
+3.32%
(+0.42) 1D
$13.09
+0.08% (+0.010)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLYM...
Open
$12.51
High
$13.16
Low
$12.42
Mkt. cap
749.00M
Avg. vol.
1.10M
Volume
6.32M
52-wk high
$13.46
52-wk low
$1.18
EPS
-$0.78
Beta
0.12
Shares outstanding
57.26M
No. of employees
29
Open
$12.51
High
$13.16
Low
$12.42
Mkt. cap
749.00M
Avg. vol.
1.10M
Volume
6.32M
52-wk high
$13.46
52-wk low
$1.18
EPS
-$0.78
Beta
0.12
Shares outstanding
57.26M
No. of employees
29
News stories
From sources across the web
About Climb Bio Inc
CEO-
Employees29
Founded2018
HeadquartersWellesley Hills, Massachusetts, United States
SectorBiotechnology
Websiteclimbbio.com
Analyst ratings
Based on 13 analysts giving stock ratings to CLYM in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for CLYM in the last 3 months.
Highest
Current $13.08
$35.00 (+167.58%)
Average
$21.56 (+64.83%)
Lowest
$17.00 (+29.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Christopher Raymond
Raymond James
Buy
Maintained
-
-
06/24/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$20.00
+52.9%
06/24/2026
Laura Chico
Wedbush
Buy
Maintained
$17.00
+30%
06/12/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
06/12/2026
Julian Harrison
BTIG
Buy
Maintained
$20.00
+52.9%
06/11/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
06/11/2026
Yatin Suneja
Guggenheim
Buy
Initiated
$35.00
+167.6%
06/08/2026
Danielle Brill
Truist Financial
Buy
Maintained
-
-
06/02/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$23.00
+75.8%
05/19/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$18.00
+37.6%
05/15/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$21.00
+60.6%
05/06/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
$22.00
+68.2%
05/05/2026
Joseph Catanzaro
Mizuho Securities
Buy
Initiated
$18.00
+37.6%
04/15/2026
Mayank Mamtani
B. Riley Securities
Buy
Initiated
$26.00
+98.8%
03/24/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
6.58M
9.07M
13.74M
9.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.10M
5.82M
5.56M
5.84M
Operating expense
10.68M
14.89M
19.30M
15.21M
Total operating expenses
10.68M
14.89M
19.30M
15.21M
Operating income
-10.68M
-14.89M
-19.30M
-15.21M
Other non operating income
-
-
-
-
EBT including unusual items
-8.67M
-12.89M
-17.52M
-13.72M
EBT excluding unusual items
-8.67M
-12.89M
-17.52M
-13.72M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-8.67M
-12.89M
-17.52M
-13.72M
Net profit margin
-
-
-
-
Earnings per share
-
-0.19
-0.26
-0.20
Interest and investment income
2.17M
2.04M
1.83M
1.51M
Interest expense
-
-
-
-
Net interest expenses
2.17M
2.04M
1.83M
1.51M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.66M
-14.86M
-19.27M
-15.17M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of CLYM
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer